12:00 AM
 | 
Oct 27, 2008
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vidaza azacitidine regulatory update

EMEA's CHMP recommended approval for Vidaza to treat myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myelogenous...

Read the full 69 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >